Yahoo
NasdaqCM - Delayed Quote USD

Bluejay Diagnostics, Inc. (BJDX)

0.8324 -0.0165 (-1.94%)
At close: September 4 at 4:00:01 PM EDT
0.8299 -0.0025 (-0.30%)
After hours: September 4 at 7:30:03 PM EDT
Chart Range Bar
Loading chart for BJDX
  • Previous Close 0.8489
  • Open 0.8394
  • Bid 0.5813 x 200
  • Ask 1.1000 x 200
  • Day's Range 0.8211 - 0.8496
  • 52 Week Range 0.8180 - 16.6800
  • Volume 88,719
  • Avg. Volume 4,925,827
  • Market Cap (intraday) 861,296
  • Beta (5Y Monthly) 0.91
  • PE Ratio (TTM) --
  • EPS (TTM) -2.2100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

bluejaydx.com

6

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BJDX
68.80%
S&P 500 (^GSPC)
12.75%

1-Year Return

BJDX
85.24%
S&P 500 (^GSPC)
18.71%

3-Year Return

BJDX
99.99%
S&P 500 (^GSPC)
70.93%

5-Year Return

BJDX
100.00%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY23
Revenue --
Earnings -2.3M
Profit Margin 0.00%

Q2

FY23

Q3

FY23

Q4

FY23

-3M
-2M
-2M
-1M
-500K
0
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -51.08%

  • Return on Equity (ttm)

    -98.89%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -7.27M

  • Diluted EPS (ttm)

    -2.2100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.6M

  • Total Debt/Equity (mrq)

    0.86%

  • Levered Free Cash Flow (ttm)

    -3.55M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: